TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$3.43 (−4.70%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Tarsus Pharmaceuticals, Inc. grew revenue 105.2% to $606.33M over the twelve months to Jun 30, 2026. Free cash flow was $56.00M.
Revenue
$606.33M
+105.2% vs. a year earlier
Operating income
-$48.54M
TTM Q2 2026
Free cash flow
$56.00M
TTM Q2 2026
EPS, diluted
-$1.09
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.02B
- P/E ratio
- –
- Price to sales
- 4.97
- Price to book
- 8.70
- Dividend yield
- 0.00%
- Free cash flow yield
- 1.86%
Fundamentals
- Revenue
- $606.33M
- Net income
- -$46.48M
- EPS, diluted
- -$1.09
- Free cash flow
- $56.00M
- Book value per share
- $7.99
- Diluted shares
- 43M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$606.33M+105.2% YoY
Operating income
-$48.54M
Net income
-$46.48M
EPS, diluted
-$1.09
Free cash flow
$56.00M
Reported periodTrailing twelve months